TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Feasibility Questionnaire regarding Patient reported tolerance of cryotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical markers of sobriety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) measured by Karnofsky Performance Scale (KPS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of participants improving on WHO-OSCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasted Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasted Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wound area regression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported outcomes assessed by EORTC QLQ C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient reported outcomes assessed by EORTC QLQ-BR45
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thoracic kyphosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in QTcF at Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QTcF at Day 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Esophageal occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with higher FNAIT risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate-dependent depression of H reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Titer of antibody against SARS-CoV-2 spike protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantity of TNF-a secreted in response to stimulation with SARS-CoV-2 spike protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PROMIS 10-item Global Health Scale - Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PROMIS 10-item Global Health Scale - Physical Functioning Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PROMIS 10-item Global Health Scale - Mental Functioning Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calories in beverage chosen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Added sugar content of beverage chosen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recognition of Environmental sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety evaluated using the Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kinesiophobia evaluated using the Tampa Kinesiophobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptoms evaluated using the Numerical Rating Scale for Symptoms Related to First Mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of common bile duct injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average Pain Intensity Over the Prior week (0 - 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain intensity between pre- and 6-months post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants exceeding 50% pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs) for Part A
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs) for Part B
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 for Part A
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 for Part B
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant abnormalities in vital signs for Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Correct Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quick Speech In Noise Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: 180 days overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of aortic dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in sleeping energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean difference in sleeping energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure Injury Staging Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent change in bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 4 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Spontaneous preterm birth <34 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Stable Disease in Monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Stable Disease in Combination Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goniometric measurement for ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and Mc Master Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concordance of Sentinel Lymph Node Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Limb volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic factors associated with vaccine-induced Guillain-Barré syndrome (GBS)
Endpoint domain: Adverse events/effects
Primary endpoint: Genetic factors associated with vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Genetic factors associated with myocarditis/pericarditis
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Chronic pain at 3 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak exhalation flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventriculitis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: best hepatic ORR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case numbers diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case numbers followed up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyoid Bone Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological profile of PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of endoscopic ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of immunosuppressive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total acne lesions on the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Identification of specific endothelial signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Iodine Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CM score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of abdominal CT scanning
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of delayed or missed or delayed intra-abdominal injuries
Endpoint domain: Adverse events/effects
Primary endpoint: progression disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Skin's Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin's Drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin's Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Geriatric Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for Dialysis in the First 30 Days Post-transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Renal Function 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Graft Survival 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative re-bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Osteoblast progenitor cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Nature and frequency of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Temperature measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: right atrial pressure (RAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Explicit recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acidity measure of vaginal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Endoscopic healing rate of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fear of surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in isokinetic strength of knee extensors and knee flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in countermovement jump (CMJ) height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum tolerated dose (MTD) or the recommended phase Ⅱ dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AE) and severe adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Neuropsychological Composite Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite Z-score of Objective Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite Z-score of Subjective Measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Completion of radical cystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hesitancy towards childhood routine immunization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COVID-19 vaccine hesitancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acute ablation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort of nasal mask
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General appreciation of nasal mask
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HF related hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Age at Type 2 skin disease onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Type of current Type 2 skin disease therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of Type 2 skin disease and selected comorbid conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of cellular and soluble actors involved in pulmonary toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: facial emotional responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported feelings of connection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cytokine Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in composite score on Client Satisfaction Questionnaire-8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-Concussion Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Error Scoring Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COGNIGRAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of Telitacicept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach Cmax (tmax) of Telitacicept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (t1/2z) of Telitacicept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived musculoskeletal discomfort during prolonged sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: The Global Perceived Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intra/Inter Operator Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures accuracy analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital-free Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Concordance between medical prescription and clinical decision support system recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients referred to the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients that enrolled in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Procedure Length Using an OCT Probe During Routine Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance indicators of diagnosis technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 3 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of treatment-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: BOLD response during gameplay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior response: Game score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ultrasound BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma concentration (Cmax) of HS-10518
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-t) of HS-10518
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature and number of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported dizziness, discomfort and stress on a ten-point scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of the apnoea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bacteria engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of Hyperoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abscess prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean monocular postoperative DCNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of eyes that achieve 0.3, 0.2, 0.1 and 0.0 logMAR monocular DCNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number and percentage of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: maximum decline of HBsAg level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric conduit necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clavien-Dindo-Classification score
Endpoint domain: Adverse events/effects
Primary endpoint: Mycoplasma pneumoniae load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cell count per area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tempa-11 Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in percent duration of pH ≥4 in 24 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with PASI Score of 75% or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External jugular vein (EJV) occlusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renal cell carcinoma recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Visual acuity at intermediate distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long Term Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants who Developed an Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of BH002
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic characteristics of BH002
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foot rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Disordered Breathing (SDB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurodevelopmental Impairment (NDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Remission Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ROI area (mm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Platelet Count by >30% or >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Bleeding Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Estimated Glomerular Filtration Rate (eGFR) by ≥30% or ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Laryngeal Mask Placement times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of failed attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of dose-limiting toxicities (DLTs) for lymphoid directed chemotherapy block
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dose-limiting toxicities (DLTs) for myeloid directed chemotherapy block
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal residual disease (MRD) negative remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes